NextCure Beheer

Beheer criteriumcontroles 3/4

De CEO NextCure is Michael Richman, benoemd in Oct2015, heeft een ambtstermijn van 9.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.04M, bestaande uit 54.7% salaris en 45.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.45% van de aandelen van het bedrijf, ter waarde € 465.40K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 4.2 jaar.

Belangrijke informatie

Michael Richman

Algemeen directeur

US$1.0m

Totale compensatie

Percentage CEO-salaris	54.7%
Dienstverband CEO	9.1yrs
Eigendom CEO	1.5%
Management gemiddelde ambtstermijn	5.1yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Michael Richman's beloning veranderd ten opzichte van NextCure's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$59m
Jun 30 2024	n/a	n/a	-US$61m
Mar 31 2024	n/a	n/a	-US$64m
Dec 31 2023	US$1m	US$572k	-US$63m
Sep 30 2023	n/a	n/a	-US$66m
Jun 30 2023	n/a	n/a	-US$70m
Mar 31 2023	n/a	n/a	-US$70m
Dec 31 2022	US$2m	US$549k	-US$75m
Sep 30 2022	n/a	n/a	-US$74m
Jun 30 2022	n/a	n/a	-US$73m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$3m	US$529k	-US$69m
Sep 30 2021	n/a	n/a	-US$68m
Jun 30 2021	n/a	n/a	-US$66m
Mar 31 2021	n/a	n/a	-US$63m
Dec 31 2020	US$6m	US$491k	-US$37m
Sep 30 2020	n/a	n/a	-US$32m
Jun 30 2020	n/a	n/a	-US$24m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$626k	US$419k	-US$34m
Sep 30 2019	n/a	n/a	-US$30m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$24m
Dec 31 2018	US$3m	US$383k	-US$23m

Compensatie versus markt: De totale vergoeding ($USD 1.04M ) Michael } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.54K ).

Compensatie versus inkomsten: De vergoeding van Michael is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Michael Richman (63 yo)

9.1yrs

Tenure

US$1,044,627

Compensatie

Mr. Michael S. Richman, MSBA, Co-founded NextCure, Inc. since 2015 and has been its Chief Executive Officer, President & Director since July 2015. Mr. Richman served as the Chief Executive Officer and Pres...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Richman	Co-Founder	9.1yrs	US$1.04m	1.45% € 465.4k
Solomon Langermann	Chief Scientific Officer	5.9yrs	US$681.59k	0.13% € 42.8k
Lieping Chen	Co-Founder & Chairman of Scientific Advisory Board	9.8yrs	geen gegevens	geen gegevens
Steven Cobourn	Chief Financial Officer	6.8yrs	US$1.01m	geen gegevens
Timothy Mayer	Chief Operating Officer	5.1yrs	geen gegevens	geen gegevens
Kevin Shaw	Senior VP & General Counsel	2.5yrs	geen gegevens	geen gegevens
Sourav Kundu	Senior Vice President of Development & Manufacturing	3.3yrs	geen gegevens	geen gegevens
Sebastien Maloveste	Senior Vice President of Business Development	1.3yrs	geen gegevens	geen gegevens
Udayan Guha	Senior Vice President of Clinical & Translational Development	1.3yrs	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2US is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Richman	Co-Founder	9.1yrs	US$1.04m	1.45% € 465.4k
Lieping Chen	Co-Founder & Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Elaine Jones	Independent Director	8.9yrs	US$67.47k	0% € 0
Mario Sznol	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
David Kabakoff	Independent Chairman of the Board	8.9yrs	US$93.16k	0.22% € 71.3k
Stephen Webster	Independent Director	5.6yrs	US$71.66k	0% € 0
Ellen Feigal	Independent Director	3.1yrs	US$61.66k	0% € 0
Stephen Miller	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Houston	Independent Director	4.2yrs	US$61.66k	0% € 0
Weiping Zou	Member of Scientific Advisory Board	3.1yrs	geen gegevens	geen gegevens
Ursula Matulonis	Member of Scientific Advisory Board	3.1yrs	geen gegevens	geen gegevens
Anne Borgman-Hagey	Independent Director	3.1yrs	US$60.66k	0% € 0

4.2yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2US wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

NextCure Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board

Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board

Recent updates

NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody

New minor risk - Share price stability

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

Insufficient new directors

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

New major risk - Revenue and earnings growth

New major risk - Share price stability

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Nextcure, Inc. Provides Year-End Clinical Pipeline Updates

NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

New major risk - Revenue and earnings growth

NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605

NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board

NextCure, Inc. Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

NextCure, Inc. Presents NC410 Data at the Extracellular Matrix Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board

High number of new directors

NextCure, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

Now 23% undervalued after recent price drop

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

NextCure, Inc. and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

High number of new directors

Independent Director Xiaoxing Xu has left the company

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell 2500 Growth Index

Nextcure and Collaborators Publish Preclinical Data on Novel Immunomedicine Nc410

Independent Director has left the company

Full year 2020 earnings released: US$1.33 loss per share (vs US$2.15 loss in FY 2019)

Revenue misses expectations

NextCure, Inc. Announces Resignation of Briggs Morrison from the Board of Directors, Effective April 1, 2021

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Nextcure, Inc

New 90-day high: €10.60

NextCure, Inc. Announces the Appointment of Han Myint as Chief Medical Officer

NextCure, Inc. Provides Updates on NC318 Clinical Program

Rosen Reminds Nextcure, Inc. Investors of Important November 20 Deadline in Securities Class Action

Revenue in line with expectations

New 90-day high: €10.30

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Against Nextcure Inc

Block & Leviton LLP Reminds Investors of Nextcure, Inc. for Violations of the Federal Securities Laws

Nextcure, Inc. Announces Resignation of Kevin N. Heller from Chief Medical Officer

Scott+Scott Attorneys At Law LLP Files Securities Class Action Against NextCure Inc

New 90-day low - €7.35

First half earnings released

New 90-day low - €7.70

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Value Index

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Index

NextCure, Inc.(NasdaqGS:NXTC) dropped from S&P Biotechnology Select Industry Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd